CVA Family Office’s Halozyme HALO Stock Holding History

CVA Family Office’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.12K	Buy	91 +41	+82%	+$2.8K	﹤0.01%	1137
2026 Q1	$3.23K	Buy	+50	New	+$3.52K	﹤0.01%	1387

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

CVA Family Office's HALO Position: Q2 2026 in Review

CVA Family Office increased its Halozyme (HALO) stake by 82% in Q2 2026, buying an estimated $2.8K and bringing the position to 91 shares worth $7.12K. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

CVA Family Office first reported a position in HALO in Q1 2026 and has held it in 2 quarters since. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

CVA Family Office held 91 shares of Halozyme worth $7.12K as of Q2 2026.
CVA Family Office bought 41 Halozyme shares in Q2 2026, an estimated $2.8K.
Halozyme made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1137 holding.
CVA Family Office first reported a position in Halozyme in Q1 2026 and has held it in 2 quarters since.
674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.